<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380003</url>
  </required_header>
  <id_info>
    <org_study_id>2004</org_study_id>
    <nct_id>NCT00380003</nct_id>
  </id_info>
  <brief_title>Efficacy Study of EVT 201 to Treat Insomnia</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy of Two Doses of EVT 201 in the Treatment of Primary Insomnia in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evotec Neurosciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evotec Neurosciences GmbH</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a compound known as EVT 201 is effective in
      treating people diagnosed with primary insomnia ( difficulty sleeping with no other
      significant contributing factor, such as depression).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Wake after sleep onset</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Latency to persistent sleep</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of awakenings</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total wake time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minutes of stages 1-4 and REM sleep</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REM latency</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported sleep variables</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual sedation measures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments including adverse events, ECgs, vital signs and routine laboratory assessments.</measure>
  </secondary_outcome>
  <enrollment>66</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVT 201</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have a diagnosis of primary insomnia

          -  over the last three months, must have a normal bedtime of between 9 pm and 1 am and a
             time in bed of at least 7 hours

          -  must be able to attend the Sleep Center for two consecutive nights on four occasions
             over a two month period

          -  must be willing and able to complete a sleep diary and questionnaires

        Exclusion Criteria:

          -  must not have a clinically significant or unstable medical condition that may
             interfere with sleep

          -  must not have a major psychiatric disorder (other than insomnia) such as depression,
             schizophrenia, bipolar disorder

          -  must not be currently using any medication know to affect sleep e.g. hypnotics,
             anxiolytics,antidepressants, antihistamines, anticonvulsants

          -  must not intentionally nap 3 (or more) times per week

          -  must not smoke more than 10 cigarettes per day and /or be able not to smoke without
             distress or discomfort for the duration of visits to the sleep laboratory ( i.e.
             approximately 12 hours)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James K Walsh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital, Sleep Medicine and Research Center, Chesterfield, MI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Petersburg Sleep Disorders Center</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sleep Disorders Center of Georgia, Peachtree Dunwoody Medical Center,5505 Peachtree Dunwoody Road, Suite 548</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield (St Louis)</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Sleep Disorders Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2006</study_first_submitted>
  <study_first_submitted_qc>September 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <last_update_submitted>January 29, 2008</last_update_submitted>
  <last_update_submitted_qc>January 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

